Paper33832018
[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].
Infectious Diseases Society of China and 6 others. Zhonghua Jie He He Hu Xi Za Zhi, 2021. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. [Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China]. Papers, record 33832018. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33832018
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].
- PubMed
Topics2
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Polymyxins | Major topic |
| China |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42244289 | Clinical efficacy and risk factors of colistin sulfate in the treatment of carbapenem-resistant Gram-negative bacilli infections: A retrospective study. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2026 | https://conductscience.org/library/papers/42244289 | PubMed |
| 42215914 | A successful individualized comprehensive therapy for carbapenem-resistant Klebsiella pneumoniae induced multifocal brain abscesses: a case report and literature review. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42215914 | PubMed |
| 42180693 | Polymyxin B-induced acute kidney injury in a burn patient: a case report and pharmaceutical care. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42180693 | PubMed |
| 41958927 | Commentary: Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41958927 | PubMed |
| 41899205 | Sulbactam-Durlobactam in the Treatment of Bloodstream Infection Due to Carbapenem-Resistant Acinetobacter baumannii: A Case Series and Literature Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899205 | PubMed |
| 41201487 | Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis. | Int J Clin Pharm | 2026 | https://conductscience.org/library/papers/41201487 | PubMed |
| 41013329 | The relationship between the alveolar epithelial lining fluid concentration of intravenous plus inhaled polymyxin B and clinical efficacy in patients with pneumonia caused by carbapenem-resistant gram-negative bacilli: a prospective cohort study. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/41013329 | PubMed |
| 40980916 | Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40980916 | PubMed |
| 40974395 | Optimizing Polymyxin B Therapy in Critical Care: Pharmacokinetic Insights and Clinical Outcomes in a Retrospective Cohort Study. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/40974395 | PubMed |
| 40895544 | Case Report: Polymyxin E-associated reversible leukopenia. | Front Immunol | 2025 | https://conductscience.org/library/papers/40895544 | PubMed |
| 40419663 | Population pharmacokinetics of colistin sulfate in critically ill patients based on NONMEM. | Sci Rep | 2025 | https://conductscience.org/library/papers/40419663 | PubMed |
| 40170884 | Aerosolized delivery resulting in high polymyxin B concentration levels in epithelial lining fluid ensures efficacy in ventilator-associated pneumonia. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40170884 | PubMed |
| 40092845 | Temporal Shifts in Etiological Agents and Trends in Antimicrobial Resistance of Bloodstream Infection in Southwest China from 2016 to 2023. | Infect Drug Resist | 2025 | https://conductscience.org/library/papers/40092845 | PubMed |
| 39830357 | Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39830357 | PubMed |
| 39174888 | Antibiotic resistance and epidemiological characteristics of polymyxin-resistant Klebsiella pneumoniae. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2024 | https://conductscience.org/library/papers/39174888 | PubMed |
| 38974043 | Polymyxins: recent advances and challenges. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38974043 | PubMed |
| 38212555 | Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases. | Infect Dis Ther | 2024 | https://conductscience.org/library/papers/38212555 | PubMed |
| 37878197 | Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. | Infection | 2024 | https://conductscience.org/library/papers/37878197 | PubMed |
| 36643845 | Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36643845 | PubMed |
| 36176436 | Commentary: Population pharmacokinetics of colistin sulfate in critically ill patients: Exposure and clinical efficacy. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36176436 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33832018
GET https://conductscience.org/api/papers/v1/33832018/cited_by?page=2